EN DE
Watch Praxis Precision Medicines Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Praxis Precision Medicines Inc (PRAX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Praxis Precision Medicines Inc stock $157, price $338, that is 53.4% below the price, quality 31 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PP Praxis Precision Medicines Inc logo Thin data Nov 11, 2026

Praxis Precision Medicines Inc

PRAX · US
Very expensive, weak quality

Our calculation puts a fair price 53% below what the stock costs today.

Mixed Growth (revenue YoY +249.5 %/yr in USD)
Insiders sold $3.6M (6M)
Fair value $157.43 · Strongly overvalued
Quality 31/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 8/100 · thin data
Thin data
Estimate

Risks from the AI analysis

🚩Key patent expiry could enable generics🚩Reliance on CDMOs for manufacturing
Watch Praxis Precision Medicines Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$386.33 $12.06 Fair Value $157.43 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $12.06 – $386.33 · fair‑value band $118.07 – $196.78 · the $337.59 price screens above the $157.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Praxis Precision Medicines in your weekly email

Every Wednesday you see whether Praxis Precision Medicines is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Show moreShow less

The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.

It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.

It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016.

Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Stock analysis

Praxis Precision Medicines Inc (PRAX) currently trades at $337.59, while our estimate is $157.43, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $118.07 (bear) to $196.78 (bull), the price of $337.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Praxis Precision Medicines Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$303M in FY2025.

Key figures

Market cap $9.8B Mid · EPS (TTM) $−12.82 · Return on equity −38.9% · Return on assets (EBIT) −92.8% (5-year average) · Revenue (TTM) $7.5M · Revenue growth (YoY) +13.5% · Free cash flow −$249M · Net cash $357M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 106% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −53%, PRAX screens richer than that median.

Fair Value

Bear $118.07 Fair Value $157.43 Bull $196.78
Price $337.59 · Downside -53.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 21
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 57
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 89
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $3.6M and none bought.

  • SaleJill DeSimoneDirector11,600 shares at $311.32$3.6MJun 24, 202610b5-1 plan
  • SaleLauren MastrocolaPrincipal Accounting Officer13,600 shares at $192.08$2.6MNov 20, 2025
  • SaleAlex NemiroffGeneral Counsel and Secretary25,130 shares at $193.08$4.9MNov 20, 2025

Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PRAX screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Praxis Precision Medicines Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Below median
Fair Value upside −53.4% · Bottom 25%
Profitability
Return on assets −32.3% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 13.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 11.20× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)67 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PRAX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PRAX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PRAX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PRAX
argenx SE ARGX $971.55 $908.40 −7% vs PRAX
CSL Limited CSL A$201.68 A$181.40 −10% vs PRAX
Moderna, Inc MRNA $250.83 $158.70 −37% vs PRAX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PRAX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PRAX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PRAX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Praxis Precision Medicines Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Praxis Precision Medicines Inc Fair Value". https://www.fairvalue-calculator.com/stock/PRAX

Frequently asked questions

Is Praxis Precision Medicines Inc (PRAX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $157.43 versus a price of $337.59, about 53% lower (overvalued).
What is the fair value of PRAX?
Our estimate for Praxis Precision Medicines Inc is $157.43 (as of Nov 11, 2026), built from audited fundamentals. The current price: $337.59.
What is the quality score of PRAX?
Praxis Precision Medicines Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Praxis Precision Medicines Inc (PRAX)?
Our calculated price target is the estimate of $157.43 (as of Nov 11, 2026). Cautious scenario $118.07, optimistic scenario $196.78. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Praxis Precision Medicines Inc stock forecast for 2026?
Our estimate puts fair value at $157.43, about 53% lower versus a price of $337.59 (overvalued). Cautious scenario $118.07, optimistic scenario $196.78. The calculation is refreshed regularly with new filings.
What is the revenue of Praxis Precision Medicines Inc (PRAX)?
Praxis Precision Medicines Inc reported trailing-twelve-month revenue of about $7.5M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Praxis Precision Medicines Inc (PRAX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Praxis Precision Medicines Inc it is $157.43 per share (as of Nov 11, 2026), against a price of $337.59.
Is Praxis Precision Medicines Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, PRAX trades above its calculated fair value: price $337.59, fair value $157.43, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRAX?
No. The price is what the market pays today ($337.59); the fair value is what the company's own numbers justify ($157.43). For Praxis Precision Medicines Inc the two are $180.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Praxis Precision Medicines Inc worth?
The market values Praxis Precision Medicines Inc at about $9.8B (market capitalisation, as of Nov 11, 2026). Per share that is $337.59; our models calculate a fair value of $157.43 per share.
What do the bullish and bearish scenarios say about PRAX?
Our models span a range for Praxis Precision Medicines Inc: cautious scenario $118.07, base $157.43, optimistic $196.78 per share (as of Nov 11, 2026, price $337.59). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Praxis Precision Medicines Inc (PRAX)?
Balance-sheet figures for Praxis Precision Medicines Inc (as of Nov 11, 2026): return on equity −38.9%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is PRAX from its 52-week high?
Praxis Precision Medicines Inc trades at $337.59, about 13% below its 52-week high of $386.33 and 106% above the low of $164.09 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $157.43 is for.
Which stocks are comparable to Praxis Precision Medicines Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Praxis Precision Medicines Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $337.59, calculated fair value $157.43 (−53%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Praxis Precision Medicines Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Praxis Precision Medicines Inc (PRAX)?
The closing price on Nov 10, 2026 was $337.59. Our estimate is $157.43, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Praxis Precision Medicines Inc right now?
The price sits above even our optimistic bull case ($196.78). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Praxis Precision Medicines Inc

How large is the market capitalisation of Praxis Precision Medicines Inc (PRAX)?
The market capitalisation of Praxis Precision Medicines Inc is $9.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Praxis Precision Medicines Inc (PRAX)?
Earnings per share at Praxis Precision Medicines Inc are $−12.82. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Praxis Precision Medicines Inc (PRAX)?
The return on equity (ROE) of Praxis Precision Medicines Inc is −38.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Praxis Precision Medicines Inc (PRAX)?
On an EBIT basis the return on assets of Praxis Precision Medicines Inc is −92.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Praxis Precision Medicines Inc (PRAX)?
Revenue at Praxis Precision Medicines Inc is growing +13.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Praxis Precision Medicines Inc (PRAX) generate?
The free cash flow of Praxis Precision Medicines Inc is −$249M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Praxis Precision Medicines Inc (PRAX) hold?
Praxis Precision Medicines Inc holds more cash than debt, $357M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Praxis Precision Medicines Inc in the live analysis

One click puts Praxis Precision Medicines Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.